Strides Pharma Science Limited

NSEI:STAR Rapporto sulle azioni

Cap. di mercato: ₹129.6b

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Strides Pharma Science Performance dei guadagni passati

Il passato criteri di controllo 0/6

Gli utili di Strides Pharma Science sono diminuiti a un tasso medio annuo di -42.5%, mentre il settore Pharmaceuticals ha visto gli utili crescere a un tasso medio annuo di 15.4%. I ricavi sono cresciuti crescere a un tasso medio annuo di 5.7%.

Informazioni chiave

-42.5%

Tasso di crescita degli utili

-42.5%

Tasso di crescita dell'EPS

Pharmaceuticals Crescita del settore17.5%
Tasso di crescita dei ricavi5.7%
Rendimento del capitale proprio-3.4%
Margine netto-1.1%
Ultimo aggiornamento sui guadagni30 Jun 2024

Aggiornamenti sulle prestazioni recenti

Recent updates

After Leaping 29% Strides Pharma Science Limited (NSE:STAR) Shares Are Not Flying Under The Radar

Aug 14
After Leaping 29% Strides Pharma Science Limited (NSE:STAR) Shares Are Not Flying Under The Radar

Investors Still Waiting For A Pull Back In Strides Pharma Science Limited (NSE:STAR)

Apr 04
Investors Still Waiting For A Pull Back In Strides Pharma Science Limited (NSE:STAR)

Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?

Feb 29
Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?

Strides Pharma Science Limited's (NSE:STAR) Shares Leap 31% Yet They're Still Not Telling The Full Story

Dec 23
Strides Pharma Science Limited's (NSE:STAR) Shares Leap 31% Yet They're Still Not Telling The Full Story

We Think Strides Pharma Science (NSE:STAR) Is Taking Some Risk With Its Debt

Sep 26
We Think Strides Pharma Science (NSE:STAR) Is Taking Some Risk With Its Debt

Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?

Jun 08
Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?

Strides Pharma Science Limited (NSE:STAR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

Aug 02
Strides Pharma Science Limited (NSE:STAR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

Is Strides Pharma Science (NSE:STAR) A Risky Investment?

Jun 25
Is Strides Pharma Science (NSE:STAR) A Risky Investment?

Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?

Dec 21
Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?

Strides Pharma Science (NSE:STAR) Has Announced That It Will Be Increasing Its Dividend To ₹2.50

Jul 28
Strides Pharma Science (NSE:STAR) Has Announced That It Will Be Increasing Its Dividend To ₹2.50

Estimating The Fair Value Of Strides Pharma Science Limited (NSE:STAR)

Apr 13
Estimating The Fair Value Of Strides Pharma Science Limited (NSE:STAR)

Should Strides Pharma Science Limited (NSE:STAR) Be Part Of Your Dividend Portfolio?

Mar 04
Should Strides Pharma Science Limited (NSE:STAR) Be Part Of Your Dividend Portfolio?

These 4 Measures Indicate That Strides Pharma Science (NSE:STAR) Is Using Debt Extensively

Feb 15
These 4 Measures Indicate That Strides Pharma Science (NSE:STAR) Is Using Debt Extensively

Can Mixed Fundamentals Have A Negative Impact on Strides Pharma Science Limited (NSE:STAR) Current Share Price Momentum?

Jan 26
Can Mixed Fundamentals Have A Negative Impact on Strides Pharma Science Limited (NSE:STAR) Current Share Price Momentum?

The Strides Pharma Science (NSE:STAR) Share Price Is Up 140% And Shareholders Are Boasting About It

Jan 11
The Strides Pharma Science (NSE:STAR) Share Price Is Up 140% And Shareholders Are Boasting About It

Who Has Been Selling Strides Pharma Science Limited (NSE:STAR) Shares?

Dec 28
Who Has Been Selling Strides Pharma Science Limited (NSE:STAR) Shares?

Are Strides Pharma Science's (NSE:STAR) Statutory Earnings A Good Guide To Its Underlying Profitability?

Dec 10
Are Strides Pharma Science's (NSE:STAR) Statutory Earnings A Good Guide To Its Underlying Profitability?

Ripartizione dei ricavi e delle spese

Come Strides Pharma Science guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.


Storia dei guadagni e delle entrate

NSEI:STAR Ricavi, spese e utili (INR Millions )
DataRicaviGuadagniSpese G+ASpese di R&S
30 Jun 2442,086-4757,9580
31 Mar 2440,511-1,2488,0340
31 Dec 2339,535-1,5257,6420
30 Sep 2337,806-2,2807,6070
30 Jun 2336,783-9247,1590
31 Mar 2336,884-2,2127,6860
31 Dec 2235,680-1,8247,3950
30 Sep 2234,976-2,2417,3850
30 Jun 2233,220-3,9096,6920
31 Mar 2230,703-4,6026,7280
31 Dec 2131,127-4,4256,6360
30 Sep 2131,504-2,8306,1200
30 Jun 2132,224-5435,8170
31 Mar 2133,1592,5455,7040
31 Dec 2030,260285,3590
30 Sep 2029,2645895,1920
30 Jun 2028,4801,2664,9060
31 Mar 2027,5204924,5790
31 Dec 1935,8282,8595,8720
30 Sep 1934,2032,1695,5360
30 Jun 1932,2487455,3460
31 Mar 1921,7848403,7070
31 Dec 1828,547-935,3490
30 Sep 1828,0901395,4200
30 Jun 1828,4514154,3630
31 Mar 1828,4515445,3340
31 Dec 1735,8101,0506,9210
30 Sep 1736,5931,1246,9310
30 Jun 1735,3571,7126,0640
31 Mar 1727,5542,3354,8600
31 Dec 1637,2372,8406,9840
30 Sep 1636,5732,4106,7600
30 Jun 1634,1892,1686,0610
31 Mar 1628,6221,3174,0260
31 Dec 1524,9011,1525,5080
30 Sep 1512,9628603,3670
30 Jun 1512,1052443,2060
31 Mar 1511,958161,9940
31 Mar 1410,728-1,8672,3290

Guadagni di qualità: STAR al momento non è redditizia.

Margine di profitto in crescita: STAR al momento non è redditizia.


Flusso di cassa libero e analisi degli utili


Analisi della crescita degli utili nel passato

Andamento degli utili: STAR non è redditizia e le perdite sono aumentate negli ultimi 5 anni a un tasso pari a 42.5% all'anno.

Accelerare la crescita: Impossibile confrontare la crescita degli utili di STAR nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia

Guadagni vs Settore: STAR non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Pharmaceuticals ( 19.3% ).


Rendimento del capitale proprio

ROE elevato: STAR ha un Return on Equity negativo ( -3.42% ), in quanto al momento non è redditizio.


Rendimento delle attività


Rendimento del capitale investito


Scoprire le aziende con forti performance passate